Form 8-K - Current report:
SEC Accession No. 0001683168-21-000974
Filing Date
2021-03-17
Accepted
2021-03-17 07:50:42
Documents
21
Period of Report
2021-03-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm 8-K 16939
2 INVESTOR PRESENTATION cns_ex9901.htm EX-99.1 27291
3 GRAPHIC image_001.jpg GRAPHIC 178128
4 GRAPHIC image_002.jpg GRAPHIC 155345
5 GRAPHIC image_003.jpg GRAPHIC 244172
6 GRAPHIC image_004.jpg GRAPHIC 140155
7 GRAPHIC image_005.jpg GRAPHIC 154626
8 GRAPHIC image_006.jpg GRAPHIC 149736
9 GRAPHIC image_007.jpg GRAPHIC 208141
10 GRAPHIC image_008.jpg GRAPHIC 244840
11 GRAPHIC image_009.jpg GRAPHIC 198835
12 GRAPHIC image_010.jpg GRAPHIC 178453
13 GRAPHIC image_011.jpg GRAPHIC 257056
14 GRAPHIC image_012.jpg GRAPHIC 189139
15 GRAPHIC image_013.jpg GRAPHIC 224364
16 GRAPHIC image_014.jpg GRAPHIC 215017
17 GRAPHIC image_015.jpg GRAPHIC 234488
18 GRAPHIC image_016.jpg GRAPHIC 220841
19 GRAPHIC image_017.jpg GRAPHIC 237893
20 GRAPHIC image_018.jpg GRAPHIC 141867
21 GRAPHIC image_019.jpg GRAPHIC 174662
  Complete submission text file 0001683168-21-000974.txt   5209540
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 21748455
SIC: 2834 Pharmaceutical Preparations